NCT06960577 2026-02-23
Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)
AstraZeneca
Phase 3 Recruiting
Clinical Trials
11 trialsNCT00003376 2023-06-22
Two-Drug Combination Chemotherapy Compared With Four-Drug Combination Chemotherapy in Treating Patients With Advanced Cancer of the Urothelium
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT00003701 2023-06-15
Combination Chemotherapy in Treating Patients With Bladder Cancer
Eastern Cooperative Oncology Group
Phase 3 Completed
NCT00002566 2021-02-23
Combination Chemotherapy With Bone Marrow Transplantation in Treating Men With Germ Cell Tumors
UNICANCER
Phase 3 Completed
NCT00030654 2020-10-22
Hormone Therapy Plus Chemotherapy in Treating Patients With Prostate Cancer
Radiation Therapy Oncology Group
Phase 3 Completed
NCT00002855 2018-10-31
Chemotherapy Plus Hormone Therapy Versus Androgen Suppression in Treating Patients With Metastatic or Unresectable Prostate Cancer
M.D. Anderson Cancer Center
Phase 3 Completed
NCT00005047 2017-06-08
4B951, Combination Chemotherapy in Treating Patients With Bladder Cancer
SWOG Cancer Research Network
Phase 3 Terminated
NCT00028756 2016-08-02
Comparison of Immediate and Delayed Adjuvant Chemotherapy in Treating Patients Who Have Undergone a Radical Cystectomy for Stage III or Stage IV Transitional Cell Carcinoma of the Bladder Urothelium
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Completed
NCT00072215 2016-07-04
Cisplatin and Ifosfamide Combined With Either Paclitaxel or Vinblastine in Treating Men With Progressive or Recurrent Metastatic Germ Cell Tumors
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT00024167 2016-03-22
Chemotherapy With or Without Strontium-89 in Treating Patients With Prostate Cancer
M.D. Anderson Cancer Center
Phase 3 Terminated
NCT00274950 2013-09-17
Observation and/or Combination Chemotherapy After Surgery or Biopsy in Treating Young Patients With Extracranial Germ Cell Tumors
National Cancer Institute (NCI)
Phase 3 Unknown